GPE Launches Virtual Reality Film on Climate Change And Education
WASHINGTON D.C., MAPUTO - Media OutReach - 23 October 2023 - The Global Partnership for Education (GPE) launched today Education...
Year: 2023
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment...
National Football League Teams Up with SES for Game Content Distribution
In a renewed partnership, SES’s hybrid distribution network to enable the NFL to reach over 35 partners in Europe, Asia...
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was...
Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRSâ€)...
Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between its financial forecast for the...
Ramagrama Stupa the Sole Undisturbed Original Stupa Containing Relics of Lord Buddha to be Preserved and Developed
LUMBINI, NEPAL - Media OutReach - 23 October 2023 - The Promised Land is pleased to announce the signing of...
FHA-HoReCa announces new initiatives and partnerships for 2024 edition, covering Technology Solutions and Talent recognition
Anticipate the debut of first-ever FSTEC Asia – catering to the surging demand for technology solutions among APAC restaurant companies...
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0%...
Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically fair representation of the eight...
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye--(BUSINESS WIRE)--#APO--Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop Meeting (WSM) of Heads of...
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œ
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œï¼ŒæŽ¨å‡ºå¤šæ¨£è—術課程，啟發創æ„æ–°æ½®æµ é¦™æ¸¯ - Media OutReach - 2023å¹´10月23æ—¥ - 在這個充滿活力的城市，一個令人振奮的消æ¯å³å°‡åœ¨è—術界掀起巨浪。MindHub Academy 和⌈廣州VV ARTç¶ç¶è—術創作 ⌋åˆä½œï¼ŒMindHub Academy是一家致力於æ供高質é‡æ•™è‚²å’Œè—術培訓的機構，而廣州VV ARTç¶ç¶è—術創作是一家充滿活力且經驗è±å¯Œçš„è—術機構。這兩家機構的åˆä½œæ¨™èªŒè‘—一個令人振奮的時刻，å³å°‡ç‚ºè—術愛好者ã€å‰µæ„éˆæ„Ÿè¿¸ç™¼è€…以åŠå‰µæ„åˆå¸è€…å¸¶ä¾†ä¸€å ´å‰æ‰€æœªæœ‰çš„è—術之旅。這個令人期待的åˆä½œå°‡æä¾›å¸ç”Ÿå€‘機會åƒèˆ‡å’Œè«§ç²‰å½©èª²ç¨‹ã€æ²™ç•«èª²ç¨‹ï¼ŒåŒæ™‚也推出襌繞畫課程ã€æµé«”畫課程ã€æ²™ç•«å·¥ä½œåŠã€å’Œè—術工作åŠç‰å¤šæ¨£èª²ç¨‹ã€‚MindHub Academyå°‡é‡æ–°å®šç¾©è—術教育，啟發新的潮æµï¼Œä¸¦ç‚ºæ¯å€‹åƒèˆ‡è€…打開創æ„的大門。 MindHub...
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG--(BUSINESS WIRE)--Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced the addition of a new...
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed Sami Jaghbir as Underwriting Manager,...
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –...
